Ligao Group (01622) receives additional guidance on the resumption of trading from the Stock Exchange
Ligao Group (01622) issued an announcement. Following the resumption guidelines issued by the Stock Exchange on May 24, 2023, the public...
Ligao Group (01622) announced 2023 interim results, achieving revenue of 3,562 billion yuan, land reserves of 14.5 million square meters
Ligao Group (01622) announced its 2023 interim results, with revenue of RMB 3,562 billion. The company...
力高集團:截至二零二三年十二月三十一日止年度的全年業績公告
力高集團:截至二零二三年六月三十日止六個月的中期業績公告
力高集團:截至二零二二年十二月三十一日止年度的全年業績公告
Redco Properties Expects Loss in First Six Months of 2023
Redco Properties Group (HKG:1622) expects a net loss ranging from approximately 175 million yuan to 225 million yuan for the six months ended 30 June 2023, compared with a net profit of approximately
Redco Properties: Narrowed Net Loss for 2023 Attributable to Decrease in Provision For Inventory >1622.HK
Redco Properties: Narrowed Net Loss for 2023 Attributable to Decrease in Provision For Inventory >1622.HK
Redco Properties: In Process of Preparing Annual Results for 2022, 2023>1622.HK
Redco Properties: In Process of Preparing Annual Results for 2022, 2023>1622.HK
Redco Properties Sees 6-Mos Loss CNY175M-Loss CNY225M For Period Ended June 30 2023 >1622.HK
Redco Properties Sees 6-Mos Loss CNY175M-Loss CNY225M For Period Ended June 30 2023 >1622.HK
Redco Properties Sees 2022 Loss CNY5.5B-Loss CNY6.5B >1622.HK
Redco Properties Sees 2022 Loss CNY5.5B-Loss CNY6.5B >1622.HK
Ligao Group (01622.HK) expects net loss for fiscal year 2023 to narrow year on year
Ligao Group (01622.HK) announced that it is expected that the Group will obtain a net loss of approximately RMB 175 million to RMB 225 million for the six months ended June 30, 2023, and a net profit of approximately RMB 185 million for the six months ended June 30, 2022. The expected shift from net profit to net loss is mainly due to the negative impact of the macroeconomic environment and the overall decline in the real estate market in China, which led to a decrease in revenue and gross margin of the Group's projects included in settlement during this period; and the decline in revenue from the repurchase of senior notes during this period.
REDCO GROUP: NOTICE OF BOARD MEETING
REDCO GROUP: (1) PROFIT WARNING; AND (2) CHANGE OF COMPANY SECRETARY, AUTHORISED REPRESENTATIVE AND PROCESS AGENT
REDCO GROUP: (1) QUARTERLY UPDATE ON STATUS OF RESUMPTION; (2) DELAY IN PUBLICATION OF THE 2023 ANNUAL RESULTS; AND (3) CONTINUED SUSPENSION OF TRADING
Redco Properties' Contracted Sales Reach 9.4 Billion Yuan in 2023
Redco Properties (HKG:1622) logged contracted sales of 9.40 billion yuan in 2023, while the contracted gross floor area reached more than 1 million square meters, a Wednesday filing said. Price (HKD):
Selected announcements | Meituan has repurchased a total of HK$2.4 billion in the first year; China Railway recently won bids for 20 major projects
Sunshine Insurance: The total premium income from the original insurance contract in 2023 was about 118.839 billion yuan; Ganfeng Lithium: The subsidiary plans to acquire no more than 5% of Mali Lithium's shares for no more than 65 million US dollars.
Ligao Group (01622.HK)'s contract sales in 2023 are about 9.403 billion yuan
Gelonghui, January 17, 丨 Ligao Group (01622.HK) announced that the contract sales achieved by the company, its subsidiaries and joint ventures in the 12 months ended December 31, 2023 were approximately RMB 9.403 billion, with a construction area of about 1.062,900 square meters.
Ligao Group (01622): Zhang Shixian was appointed as company secretary, authorized representative and agent for legal proceedings
Ligao Group (01622) issued an announcement. Huang Shimin has resigned as company secretary; authorized representative; and agent for legal process documents...
REDCO GROUP: PROFIT WARNING
Selected Announcements|Ping An of China clarifies: Reports about being asked to acquire Country Garden are untrue; Yuexiu Real Estate's sales during the year increased by about 33% year-on-year
Shell-W announced its third quarter results, with net revenue of 17.8 billion yuan, up 1.2% year on year; China Biopharmaceuticals sold shares in three commercial distribution companies at a total valuation of about 210 million yuan.
No Data